Simvastatin Plus Rifaximin in Decompensated Cirrhosis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The main purpose of this study is to investigate whether the combination of two different drugs, simvastatin and rifaximin, is safe in the treatment of patients with decompensated cirrhosis. The secondary purpose is to see if this combination results in an improvement in inflammation markers in patients with cirrhosis and in an improvement in analytic parameters of progression of liver disease.
Epistemonikos ID: 67bfcd8ee0f4800a3eec57ae1841d47d218802fa
First added on: May 20, 2024